L. Brinkman et al., BRONCHIAL AND CUTANEOUS RESPONSES IN ATOPIC-DERMATITIS PATIENTS AFTERALLERGEN INHALATION CHALLENGE, Clinical and experimental allergy, 27(9), 1997, pp. 1043-1051
Background Atopic dermatitis (AD) is often associated with allergic as
thma (AA). Inhalation of allergens influences the activity of AA but t
he effect on the skin in AD is unclear. Objectives We evaluated the de
gree of bronchial hyperresponsiveness to methacholine in eight AD pati
ents with AA (AD(+)) and eight AD patients without AA (AD(-)) and stud
ied bronchial and cutaneous responses after allergen inhalation challe
nge. Methods All patients were treated in hospital for their eczema wi
th tar ointment (pix liquida) and orally administered antihistamines (
mean hospital stay 37 days). After clearing of the skin lesions allerg
en inhalation challenge was performed. Cutaneous responses were studie
d by measuring the 'Costa' score before and 24 h after allergen inhala
tion challenge. Results The median value of the provocative concentrat
ion of methacholine causing a 20% fall (PC20 Mch) in forced expiratory
volume in 1 second (FEV1) was significantly higher in the AD(-) group
compared to the AD(+) group with median values of 10.70 and 0.60 mg/m
L, respectively. These values did not change significantly in both gro
ups during hospital stay. After challenge all AD(+) patients showed ea
rly and late asthmatic responses whereas only four AD(-) patients show
ed early asthmatic responses (mean values of the maximal fall in FEV1
during the EAR 37%/16% and in PEF during the LAR 27%/4% for AD(+) and
AD(-) patients, respectively). The 'Costa' score increased in both gro
ups (mean score before 19.1/24.4 and after challenge 26.8/26.9 for AD(
+) and AD-patients, respectively). The increase in the AD(+) group was
significantly higher compared with the AD(-) group (P = 0.016), Concl
usion We conclude that allergen inhalation challenge causes a flare up
of the skin lesions in atopic dermatitis patients. This was more prom
inent in atopic dermatitis patients who already suffered from an IgE-m
ediated allergic inflammation in the lung.